Kopra Bio

Executive Summary

Kopra Bio is a privately held, San Francisco-based biotech company developing next-generation cancer immunotherapies. Its proprietary gene therapy platform genetically reprograms tumor cells into localized bio-factories that secrete therapeutic proteins, such as cytokines, enabling autonomous tumor destruction. This approach aims to overcome the limitations of systemic cytokine therapies, including toxicity and poor tumor penetration, by converting malignant cells into sustained sources of immunomodulatory agents. The company is focused on solid tumor oncology and has a preclinical pipeline targeting multiple indications. The company was founded in 2020 and has raised $150 million in total funding, reflecting strong investor confidence in its novel approach. Kopra Bio is currently in the preclinical stage, advancing its lead candidates toward the clinic. With a substantial financial runway and a technology platform that addresses key challenges in cancer immunotherapy, the company is well-positioned to achieve important milestones in the near term. Key upcoming catalysts include the presentation of preclinical data at major medical conferences, the filing of an Investigational New Drug (IND) application, and potential strategic partnerships to accelerate development.

Upcoming Catalysts (preview)

• Q2 2026Preclinical data presentation at a major oncology conference (e.g., ASCO or SITC)90% success
• H1 2027IND submission for lead candidate60% success
• H2 2026Partnership or licensing deal for platform technology50% success